

1 **Role of β -lactamases and efflux pumps in multidrug resistance in *Pseudomonas***
2 ***aeruginosa* isolated from patients in the Intensive Care Unit in the northeast of**
3 **Brazil**

4 Marília S. Maia ¹ ²#, Lavouisier F.B. Nogueira ¹ ²#, Marco A.F Clementino ¹ ²#, Jose
5 Q.S. Filho ¹ ³, Ila F.N. Lima ⁴, José K. Sousa ¹, Deiziane V.S. Costa ¹, Jorge L.N.
6 Rodrigues ⁴, Luciana V.C. Fragoso ⁴, Alexandre Havt ¹ ², and Aldo A.M. Lima ¹ ² ³ *

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

¹ Institute of Biomedicine, School of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
² Postgraduate Medical Microbiology Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
³ Postgraduate Medical Sciences Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
⁴ Hospital Universitário Walter Cantídio, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
* Correspondence: alima@ufc.br
autores contribuíram igualmente para este trabalho
e-Mails: mmaia800@gmail.com, lavouisier@gmail.com, mclementino@ufc.br,
jquirinof@gmail.com, ila.lima@ebserh.gov.br, jorge1207@gmail.com,
luciana.vladia@gmail.com, ahavt@ufc.br, alima@ufc.br

22 **Abstract**

23 *Pseudomonas aeruginosa* is an opportunistic pathogen of great clinical relevance in
24 intensive care units (ICU), mainly due to its high resistance to various antimicrobials,
25 which sometimes makes effective treatment impossible, leading to high morbidity and
26 mortality in patients in critical situations. In this study, we aimed to detect variants of
27 genes encoding β -lactamases and efflux pumps in *P. aeruginosa* isolates resistant to β -
28 lactams, fluoroquinolones and aminoglycosides. All genes belonging to the subfamilies
29 were included in the study: *bla*_{SHV}, *bla*_{TEM}, *bla*_{NDM}, *bla*_{KPC}, *bla*_{GES}, *bla*_{CTX-M}. In addition,
30 we investigate the most relevant variants of the *bla*_{OXA} subfamily and genes belonging
31 to the efflux pumps of the Mex family. We tested 54 isolates of *P. aeruginosa*, finding a
32 high prevalence of phenotypic resistance to the antimicrobials piperacillin with
33 tazobactam, ceftazidime, cefepime, imipenem and meropenem, with a high positivity in
34 the presence of resistance genes related to carbapenems and spectrum β -lactamases
35 extended, mainly for the *bla*_{KPC} genes with 81.49%, followed by *bla*_{CTXM-2} with 72.22%
36 and *bla*_{CTXM-1} with 66.66%. In relation to the presence of Mex family efflux pumps
37 there was a rate of 100% of positivity. These results suggest that the *P. aeruginosa*
38 strains isolated have an arsenal of genes encoding β -lactamases capable of inducing
39 phenotypic patterns of resistance to several antimicrobials commonly used for these
40 infections, making treatment difficult for the patients in this clinical ward.

41 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

42 **Key words:** *P. aeruginosa*; Antimicrobial Resistance; β -lactamases genes; efflux pumps
43 genes; Intensive Care Unit.

44

45

46 **Introduction**

47 Antimicrobial-resistant Gram-negative bacteria (GNB) are of particular concern
48 worldwide due to their high morbidity and mortality, particularly in intensive care units
49 (ICUs) [1]. The emergence and spread of microbial resistance is a global problem that
50 has profound consequences for public health and the economy [2].

51 Due to the selective pressure exerted by the frequent use of antimicrobials and
52 the long stay of patients with compromised immune systems, infections related to
53 multidrug-resistant (MDR) microorganisms are prevalent in ICU facilities [3,4].
54 Healthcare-associated infections (HAIs) caused by MDR are considered a threat to
55 public health, as they limit or even make available therapeutic options unfeasible, which
56 increases the severity and, consequently, the morbidity and mortality rates of those
57 affected, increasing patient length of stay and hospital costs [1].

58 In this scenario, *Pseudomonas aeruginosa*, an important opportunistic Gram-
59 negative pathogen that causes a variety of infectious diseases, has acquired resistance to
60 several antimicrobials in recent times [5,6]. According to the latest antimicrobial
61 resistance surveillance report from the European Center for Disease Prevention and
62 Control (ECDC), who evaluated *P. aeruginosa* isolates from 2013 to 2016, the average
63 of *P. aeruginosa* isolates with combined resistance (resistance to three or more
64 antimicrobial groups, including carbapenems) was 12.9% [7]. Furthermore, a study
65 carried out in Singapore observed a percentage of 11.5% of health-related infections
66 caused by *P. aeruginosa*, in which 23% of these isolates were resistant to carbapenems
67 [8]. *P. aeruginosa* is included in the “critical” category of the World Health
68 Organization (WHO) priority list of bacterial pathogens for which research and
69 development of new antimicrobials are urgently needed [1].

70 The main mechanisms involved in antimicrobial resistance in *P. aeruginosa*
71 strains are enzymatic mechanisms, where β -lactamases stand out, and efflux pumps.
72 [5,9]. *P. aeruginosa* isolates contain a variety of β -lactamases, such as the
73 carbapenemases KPC, GES, IMP, VIM, NDM and SPM, and are distributed throughout
74 the world [10,11,12].

75 Efflux pumps are related to resistance to several antimicrobials, particularly
76 those belonging to the AcrAB-TolC and Mex pump families belonging to the
77 nodulation-division resistance superfamily (RND). Efflux pumps not only mediate
78 intrinsic and acquired microbial resistance, but are also involved in other functions,
79 including bacterial stress response and pathogenicity [13,14,15].

80 Based on this, we sought to detect variants of genes encoding β -lactamases and
81 efflux pumps, belonging to the RND superfamily, in *P. aeruginosa* isolates resistant to
82 β -lactams, fluoroquinolones and aminoglycosides isolated from patients admitted to an
83 intensive care ward a tertiary care health unit in the city of Fortaleza-CE, with the
84 purpose of tracing the resistance profile of the strains isolated in the health unit in
85 question.

86 **Material and methods**

87 **Obtaining bacterial isolates and identification**

88 For the following study, 259 samples were collected from patients admitted to
89 the clinical ICU of a tertiary care health unit in the city of Fortaleza-CE, who presented
90 an infectious condition (defined by the attending ward physicians) involving different
91 anatomical sites. Those microorganisms that were identified as Gram-negative bacteria,
92 resistant to one or more groups of antimicrobials were included: β -lactams,
93 fluoroquinolones, aminoglycosides, macrolides, and glycopeptides. These samples were
94 made available for the study through approval from the research ethics committee of the
95 health unit in question (n° 3.276.113).

96 With the aim of diagnosing potential etiological agents, blood culture samples
97 and other noble liquids were inoculated in specific bottles and incubated in the
98 equipment BacT/Alert® 3D (BioMérieux, Marcy l'Etoile, France). The other biological
99 materials were sown in specific culture media using a qualitative or quantitative sowing
100 technique, in order to obtain isolated colonies. Plates were incubated at $37\pm 2^\circ\text{C}$ for 18-
101 24 hours.

102 The bacterial isolates were identified and tested for their susceptibility to
103 antimicrobials using the automated method VITEK® 2 Compact (BioMérieux, Marcy
104 l'Etoile, France), according to the manufacturer's recommendations. Minimum
105 inhibitory concentrations were interpreted according to the Clinical and Laboratory
106 Standards Institute [16] and with the Brazilian committee on antimicrobial susceptibility
107 testing [17,18]. For quality control of sensitivity tests, strains from the American Type

108 Culture Collection (ATCC) were used. Specimens that had a resistance profile that fit
109 the research objectives were included in the study.

110 Selection of analyzed strains

111 A total of 258 isolates were analyzed, among which those identified as *P.*
112 *aeruginosa* were included in this study. Strains of *P. aeruginosa* resistant to one or
113 more groups of β -lactam antimicrobials, fluoroquinolones and aminoglycosides were
114 then used to investigate their genetic resistance profile. MDR was defined as multidrug
115 resistant to ≥ 1 agent in ≥ 3 classes of antimicrobials and extending drug resistance
116 (XDR) as drug susceptibility to ≤ 2 classes of antimicrobials agents.

117 Extraction of bacterial DNA

118 The isolates maintained in trypticase soy broth were incubated overnight in a
119 bacteriological oven at 37°C, at 200 rpm, for subsequent extraction of bacterial DNA.
120 To extract genetic material, the Wizard Genomic DNA Purification extraction and
121 purification kit was used (Promega, Madison, USA), according to the manufacturer's
122 recommendations.

123 After extraction, all samples were quantified by spectrophotometry using the
124 NanoDrop™ 2000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and
125 stored in a -80°C freezer until used in the experiments.

126 Detection of resistance-related genes by molecular biology

127 The selected strains of *P. aeruginosa* were analyzed by real-time PCR (qPCR)
128 using QuantStudio 3® (Applied Biosystems, Massachusetts, USA), using specific
129 primers, for the detection of 13 genes encoding efflux pumps (**Table 1**) and 14 genes
130 encoding β -lactamases described by Nogueira and collaborators [19]. Reactions were
131 standardized using positive controls and negative controls (milliQ water) to determine
132 the most efficient qPCR conditions.

133 **Table 1** Description of genes related to encoding efflux pumps.

Efflux pumps	Gene	Function	Primers	Primer sequence (5'-3')	Product size (bp)	At (°C)
MexAB-OprM	mexA	membrane fusion protein	MexA F	GACAAGTGGCTGGTTACCGA	96	63
			MexA R	CACGGTCTTCACCTCGACAC		
	mexB	Inner membrane	MexB F	GTCGATTCCGTTCTCGGTGA	158	65

		transporter	MexB R	ACTCCACGATGAGAATGGCG		
MexCD-OprJ	mexC	membrane fusion protein	MexC F	CGTGCAATAGGAAGGATCGG	104	60
			MexC R	TCCACCGGCAACACCATTT		
	mexD	Inner membrane transporter	MexD F	TACACCCTGATCCCGTCCAT	170	64
			MexD R	ATGATCCGCTCGACGTTCTC		
MexEF-OprN	mexE	membrane fusion protein	MexE F	CTGAGCTTCACCCGGATCAC	140	64
			MexE R	GCGTCGAAGTAGGCGTAGAC		
	mexF	Inner membrane transporter	MexF F	TCATCAAGGTCAGCGACACC	169	64
			MexF R	CACTCGTAGGTCATGCCGTT		
MexGHI-OpmD	mexG	membrane protein	MexG F	TGCAGCGCTTCATCGATAACT	120	64
			MexG R	GGCTGGCCTGATAGTCGAAC		
	mexH	membrane fusion protein	MexH F	TCATCAAGGTCAGCGACACC	124	65
			MexH R	CACTCGTAGGTCATGCCGTT		
MexVW-OprM	mexV	membrane fusion protein	MexV F	TACTGTTCCTTTCCGGCGAC	170	61
			MexV R	TTCGCTTTTCGAGATGGCCT		
	mexW	membrane protein	MexW F	CCTCGGTCTACATCGGCATC	181	65
			MexW R	CCGAGGGTCTTCACTTTC		
MexXY-OprM	mexX	membrane protein	MexX F	TGCTGTTCAGATCGACCCT	127	60
			MexX R	TCCTTGATCAGGTCGGCGTA		
	mexY	membrane fusion protein	MexY F	GTCAACCAAATGACCGCCAC	134	65
			MexY R	ATGTTGTAGCTCACGCCCTC		

134 At= Annealing temperature

135 Bp= Base pairs; Primer F = Forward; Primer R = Reverse

136 Data Analysis

137 Fisher's test was used to compare the proportion of occurrence of a variable
 138 between groups. The confidence interval was 95% and the test was considered
 139 statistically significant when $P < 0.05$, using the IBM Statistical Package for the Social
 140 Sciences Version 21 program (SPSS Statistics Software, Nova York, EUA).

141 Results

142 Prevalence of *P. aeruginosa* in the study

143 During the period of this study, 258 Gram-negative bacteria were isolated, of
 144 which 20.9% (54/258) were identified as *P. aeruginosa*, which were isolated from
 145 different anatomical sites of hospitalized patients. The tracheal aspirate was the sample
 146 that obtained the highest number of *P. aeruginosa* isolates with 74.1% (40/54), followed
 147 by blood samples with 11.11% (6/54), bronchoalveolar lavage 7.40 % (4/54), of
 148 abdomen 1.85% (1/54), of tissue fragment 1.85% (1/54), of sacral eschar 1.85% (1/54)
 149 and of tendon 1, 85% (1/54).

150 Antimicrobial resistance phenotype tested in *P. aeruginosa* isolates

151 Fifteen antimicrobials from different classes were tested, in which *P.*
 152 *aeruginosa* isolates obtained a resistance rate of 100% to cefoxitin (32/32),

153 ceftriaxone (25/25), cefuroxime axetil (32/32) and tigecycline (32/32), thus
154 confirming the intrinsic resistance of the pathogen to these antimicrobials. The
155 combination of piperacillin with tazobactam obtained a rate of 74.4% (32/43),
156 followed by ceftazidime and cefepime both with the same percentage of 63.4%
157 (33/52), imipenem with 61.2% (30/ 49), meropenem with 56.2% (27/48),
158 ciprofloxacin 54.9% (28/51), gentamicin 41.5% (22/53) and, finally, amikacin with
159 28.3% (15/ 53), as shown in **Figure 1**. All tested isolates did not demonstrate a
160 phenotype of resistance to colistin, ceftazidime / avibactam and
161 ceftolozone/tazobactam.

162

163 **Figure 1.** Prevalence of *P. aeruginosa* isolates resistant to β -lactam antimicrobials
164 (A) and aminoglycosides, quinolones and glycylicycline (B) evaluated, demonstrating
165 a phenotypic profile of resistance to multiple antimicrobials in more than 50% of the
166 isolates, with the exception of colistin, ceftazidime/ avibactam, ceftolozone/
167 tazobactam, gentamicin and amikacin.

168 The tested isolates of *P. aeruginosa* obtained a percentage of 61.11% (33/54)
169 for MDR microorganisms, followed by a percentage of 55.5% (30/54) for XDR
170 microorganisms and a percentage of 46.2% (25/54) for carbapenem-resistant
171 microorganisms.

172 **Detection of resistance genes in *P. aeruginosa* isolates by qPCR**

173 For the detection of genes encoding β -lactamases, the highest percentage
174 found was the *bla*_{KPC} gene with 81.49% (44/54), followed by *bla*_{CTXM-2} with 72.22%
175 (39/54), *bla*_{CTXM-1} with 66.66% (36/54), *bla*_{CTXM-5} with 59.25% (32/54), *bla*_{SHV} with
176 40.74% (22/54), *bla*_{TEM} and *bla*_{OXA-23-like} with 38.89% (21/54), *bla*_{NDM} with 29.6%
177 (16/54), *bla*_{GES} and *bla*_{OXA-51-like} with 24% (13/54), *bla*_{OXA-24/40-like} with 20.4% (11/54),
178 *bla*_{CTXM-3} with 11.11% (6/54), *bla*_{CTXM-4} with 9.26% (5/54) and there was no detection
179 of the *bla*_{OXA-48-like} gene in the isolates, as shown in **Figure 2**, grouped according to
180 the Ambler classification.

181

182 **Figure 2.** Prevalence of β -lactam resistance genes among *P. aeruginosa* isolates,
183 grouped according to the Ambler classification, (A) in which there is a high detection

184 rate for class A ESBL (*bla*_{CTX-M} do clade 2, 1 and 5 respectively; *bla*_{SHV}; *bla*_{TEM}), (B)
 185 marked presence of the *bla*_{KPC} carbapenemase, (C) in addition to the identification of
 186 *bla*_{OXA-23-like}, *bla*_{OXA-51-like} and *bla*_{OXA-24/40-like} commonly associated with *Acinetobacter*
 187 *baumannii* strains.

188 Association of the presence of resistance genes with the resistance phenotype

189 The association between the prevalence of the 14 genes encoding β-lactamases
 190 and the β-lactam resistance phenotype identified in *P. aeruginosa* isolates was
 191 evaluated. The distribution of the percentage of genes detected in the isolates tested
 192 for the antimicrobials cefepime and ceftazidime showed a higher positivity rate for
 193 the genes *bla*_{KPC}, *bla*_{CTXM-2}, *bla*_{CTXM-1}, *bla*_{CTXM-5}, *bla*_{SHV} with 82.7% (43/52), 75%
 194 (39/52), 69.2% (36/52), 61.5% (32/52) and 42.3% (22/52), respectively. The presence
 195 of the *bla*_{TEM} and *bla*_{OXA-23-like} genes were associated with phenotypic resistance to the
 196 antimicrobials cefepime and ceftazidime (P= 0.017; OR 5.66; 95% CI 1.38-23.21)
 197 and (P=0.041; OR 3.98; 95% CI 1.08 – 14.58), respectively, as shown in **Table 2**.

198 **Table 2** Percentage of positivity of genes encoding β-lactamases in *P. aeruginosa*
 199 isolates in the groups resistant and susceptible to the antimicrobials cefepime and
 200 ceftazidime.

Coding genes β-lactamases	Total N=52(%)	Resistant N=33(%)	Susceptible N=19(%)	P valor	OR	95% CI
<i>bla</i> _{KPC}	43 (82.7)	27 (81.8)	16 (84.2)	1.0000	0.84	0.18 – 3.85
<i>bla</i> _{CTXM-2}	39 (75)	25 (75.8)	14 (73.7)	1.0000	1.11	0.30 – 4.07
<i>bla</i> _{CTXM-1}	36 (69.2)	24 (72.7)	12 (63.2)	0.5405	1.55	0.46 – 5.20
<i>bla</i> _{CTXM-5}	32 (61.5)	19 (57.6)	13 (68.4)	0.5579	0.62	0.19 – 2.05
<i>bla</i> _{SHV}	22 (42.3)	13 (39.4)	9 (47.37)	0.3969	0.58	0.18 – 1.82
<i>bla</i> _{OXA-23-like}	21 (40.4)	17 (51.5)	4 (21)	0.041*	3.98	1.08 – 14.58
<i>bla</i> _{TEM}	20 (38.5)	17 (51.5)	3 (15.8)	0.017*	5.66	1.38-23.21
<i>bla</i> _{NDM}	16 (30.7)	10 (30.3)	6 (31.6)	1.0000	0.94	0.27 – 3.19
<i>bla</i> _{GES}	13 (25)	8 (24.2)	5 (26.3)	1.0000	0.89	0.24 – 3.27
<i>bla</i> _{OXA-51-like}	13 (25)	11 (33.3)	2 (10.5)	0.0987	4.25	0.82 – 21.79
<i>bla</i> _{OXA-24/40-like}	10 (19.2)	8 (24.2)	2 (10.5)	0.2925	2.72	0.51 – 14.42
<i>bla</i> _{CTXM-3}	6 (11.5)	3 (9)	3 (15.8)	0.6563	0.53	0.09 – 2.95

<i>bla</i> _{CTXM-4}	5 (9.3)	4 (12.1)	1 (5.3)	0.6410	2.48	0.25 – 24.02
<i>bla</i> _{OXA-48-like}	0	0	0	0	0	0

201 OR= Odds ratio; CI= Confidence interval.

202 The most frequently identified genes in the isolates tested for the antimicrobial
 203 piperacillin in combination with the β -lactamase inhibitor tazobactam were *bla*_{KPC},
 204 *bla*_{CTXM-2}, *bla*_{CTXM-1}, *bla*_{CTXM-5}, *bla*_{SHV} and *bla*_{OXA-23-like} with percentages of 81.4% (
 205 35/43), 74.4% (32/43), 67.4% (29/43), 65.1% (28/43), 41.8% (18/43) and 41.8% (
 206 18/43), respectively. There was no statistical significance between the genes studied
 207 and the phenotype.

208 The percentage of positivity of the genes encoding β -lactamases detected in
 209 the isolates tested for the antimicrobial imipenem indicated a higher positivity rate for
 210 the genes *bla*_{KPC}, *bla*_{CTXM-2}, *bla*_{CTXM-1}, *bla*_{CTXM-5} and *bla*_{SHV} with percentages of
 211 79.6% (39/49), 71.4% (35/49), 67.3% (33/49), 57.1% (28/49) and 38.7% (19/49),
 212 respectively. The presence of the *bla*_{TEM} gene achieved statistical significance with
 213 phenotypic resistance to the antimicrobial imipenem (P=0.018; OR 5.33; 95% CI
 214 1.28-22.20), as shown in **Table 3**.

215 **Table 3** Percentage of positivity of genes encoding β -lactamases in *P. aeruginosa*
 216 isolates in the resistant and susceptible groups to the antimicrobial imipenem.

Coding genes β -lactamases	Total N=49(%)	Resistant N=30(%)	Susceptible N=19(%)	P valor	OR	95% CI
<i>bla</i> _{KPC}	39 (79.6)	24 (80)	15 (78.9)	1.0000	1.06	0.25 – 4.41
<i>bla</i> _{CTXM-2}	35 (71.4)	20 (66.6)	15 (78.9)	0.5185	0.53	0.13 – 2.03
<i>bla</i> _{CTXM-1}	33 (67.3)	19 (63.3)	14 (73.7)	0.5412	0.61	0.17 – 2.18
<i>bla</i> _{CTXM-5}	28 (57.1)	15 (50)	13 (68.4)	0.2467	0.46	0.13 – 1.53
<i>bla</i> _{SHV}	19 (38.7)	10 (33.3)	9 (47.3)	0.3774	0.55	0.17 – 1.80
<i>bla</i> _{OXA-23-like}	18 (36.7)	13 (43.3)	5 (26.3)	0.3621	2.14	0.61 – 7.48
<i>bla</i> _{TEM}	18 (36.7)	15 (50)	3 (15.7)	0.018*	5.33	1.28 – 22.20
<i>bla</i> _{NDM}	15 (30.6)	7 (23.3)	8 (42.1)	1.0000	0.87	0.27 – 2.81
<i>bla</i> _{OXA-51-like}	12 (24.5)	10 (33.3)	2 (10.5)	0.0948	4.25	0.81 – 22.14
<i>bla</i> _{GES}	12 (24.5)	6 (20)	6 (31.6)	0.4975	0.54	0.14 – 2.02
<i>bla</i> _{OXA-24/40-like}	8 (16.3)	6 (20)	2 (10.5)	0.4583	2.12	0.38 – 11.83

<i>bla</i> _{CTXM-3}	5 (10.2)	3 (10)	2 (10.5)	1.0000	0.94	0.14 – 6.25
<i>bla</i> _{CTXM-4}	3 (6.1)	3 (10)	0	0.2730	4.96	0.24 – 101.7
<i>bla</i> _{OXA-48-like}	0	0	0	0	0	0

217 OR= Odds ratio; CI= Confidence interval.

218 The distribution of the percentage of positivity of the genes encoding β -
 219 lactamases detected in the isolates tested for the antimicrobial meropenem showed a
 220 higher rate for the genes *bla*_{KPC}, *bla*_{CTXM-2}, *bla*_{CTXM-1}, *bla*_{CTXM-5} and *bla*_{SHV} with
 221 percentages of 79.6% (39/49), 71.4% (35/49), 67.3% (33/49), 57.1% (28/49) and 38.7%
 222 (19/49), respectively. The presence of *bla*_{TEM} and *bla*_{OXA-51-like} genes achieved statistical
 223 significance with phenotypic resistance to the antimicrobial meropenem (P= 0.034; OR
 224 4.57; 95% CI 1.21-17.23) and (P=0.043; OR 5.58; 95% CI 1.06 – 29.20), respectively,
 225 as shown in **Table 4**.

226 **Table 4** Percentage of positivity of genes encoding β -lactamases in *P. aeruginosa*
 227 isolates in the resistant and susceptible groups to the antimicrobial meropenem.

Coding genes β -lactamases	Total N=48(%)	Resistant N=27(%)	Susceptible N=21(%)	P valor	OR	95% CI
<i>bla</i> _{KPC}	38 (79.1)	21 (77.7)	17 (80.9)	1.0000	0.82	0.19 – 3.40
<i>bla</i> _{CTXM-2}	35 (72.9)	18 (66.6)	17 (80.9)	0.3377	0.47	0.12 – 1.81
<i>bla</i> _{CTXM-1}	35 (72.9)	19 (70.3)	16 (76.2)	0.7502	0.74	0.20 – 2.72
<i>bla</i> _{CTXM-5}	28 (58.3)	13 (48.1)	15 (71.4)	0.1437	0.37	0.11 – 1.24
<i>bla</i> _{SHV}	21 (43.7)	10 (37)	11 (52.4)	0.3820	0.53	0.16 – 1.70
<i>bla</i> _{OXA-23-like}	19 (39.5)	13 (48.1)	6 (28.6)	0.2369	2.32	0.69 – 7.79
<i>bla</i> _{TEM}	18 (37.5)	14 (51.8)	4 (19)	0.034*	4.57	1.21 – 17.23
<i>bla</i> _{NDM}	16 (33.3)	7 (25.9)	9 (42.8)	0.2373	0.46	0.13 – 1.58
<i>bla</i> _{OXA-51-like}	12 (25)	10 (37)	2 (9.5)	0.043*	5.58	1.06 – 29.20
<i>bla</i> _{GES}	13 (27)	6 (22.2)	7 (33.3)	0.5161	0.57	0.15 – 2.06
<i>bla</i> _{OXA-24/40-like}	8 (16.6)	6 (22.2)	2 (9.5)	0.4371	2.71	0.48 – 15.11
<i>bla</i> _{CTXM-3}	6 (12.5)	3 (11.1)	3 (14.3)	1.0000	0.75	0.13 – 4.16
<i>bla</i> _{CTXM-4}	2 (4.2)	2 (7.4)	0	0.4973	4.21	0.19 – 92.73
<i>bla</i> _{OXA-48-like}	0	0	0	0	0	0

228 OR= Odds ratio; CI= Confidence interval.

229 The genes that encode the efflux pumps of the MEX family were evaluated by
230 operon, in which the distribution of the percentage of positivity found in the tested
231 isolates was 100% for the genes MEX-AB, MEX-EF, MEX-GH, MEX-VW, MEX-XY
232 and followed by a percentage of 96.3% for the MEX-CD gene. No statistical tests were
233 performed regarding efflux pumps due to the high positivity of the genes.

234 Discussion

235 *P. aeruginosa* is an opportunistic pathogen with considerable clinical importance
236 in intensive care units, mainly due to its high resistance to several antimicrobials,
237 making effective treatment impossible, leading to high morbidity and mortality in these
238 patients in critical situations [20].

239 This study found a prevalence of 20.9% of colonization by this microorganism,
240 among Gram-negative isolates resistant to at least one antimicrobial, which represents a
241 similar percentage with other studies, as demonstrated in a report issued by ANVISA
242 [21], where *P. aeruginosa* was the third most isolated microorganism among Gram-
243 negative bacteria reported in bloodstream infections, with a percentage of 16.2%. In the
244 United States, Sader and collaborators, analyzing samples of Gram-negative bacteria
245 isolated from ICU and non-ICU patients, collected in 70 hospital centers, from 2018 to
246 2020, found a prevalence of 23.5% of *P. aeruginosa* isolated in patients admitted to
247 ICU [22]. Dunphy and collaborators carried out a study in outpatient and hospital
248 environments in regions of Virginia, United States, over a period of one year (2019-
249 2020), collecting several samples, in which they identified a prevalence of 60% of *P.*
250 *aeruginosa* isolates from different anatomical sites, analyzing 971 isolates collected
251 from 590 patients [23], in which these studies demonstrate a variability in the detection
252 rate of this pathogen.

253 In this study, the largest number of *P. aeruginosa* isolates was obtained through
254 bronchial lavage secretions with a percentage of 74.1%, similar results were reported in
255 other studies in which *P. aeruginosa* was the most isolated pathogen in lung secretions
256 (bronchial lavage and tracheal aspirate) [23,24]. Respiratory infections caused by this
257 pathogen are quite common, especially in hospital environments, and may be related to
258 the handling of invasive procedures on patients, such as tracheal intubation, aspirations
259 and the need for mechanical pulmonary ventilation [11,20].

260 In order to identify the phenotypic profile of antimicrobial resistance of *P.*
261 *aeruginosa* strains isolated in the hospital environment, antimicrobials from different

262 classes were tested, in which the highest resistance rate of *P. aeruginosa* isolates was
263 100% for cephalosporins of second and third generation cefoxitin, ceftriaxone and
264 cefuroxime axetil. Several studies corroborate this result demonstrating that the only
265 third generation cephalosporin with action on strains of *P. aeruginosa* is ceftazidime
266 [25,26].

267 In agreement with the findings of this study, research carried out in the United
268 States by Sader and collaborators [22] on *P. aeruginosa* strains collected over a two-
269 year period and a study carried out in Rio de Janeiro over a 20-year period [27], found
270 similar results for the antimicrobials piperacillin with tazobactam, ceftazidime,
271 cefepime and meropenem in strains of *P. aeruginosa*. These studies indicated a growing
272 increase in the rate of resistance to antimicrobials over the years.

273 Regarding third-generation cephalosporins in combination with β -lactamases
274 inhibitors (ceftazidime with avibactam and ceftolozone with tazobactam), in our study
275 there was no detection of the resistance phenotype. This result is in line with what was
276 expected since ceftolozone with tazobactam is an antipseudomonal antimicrobial that
277 acts on multidrug-resistant strains of *P. aeruginosa* [28,29]. The antimicrobial
278 ceftazidime with avibactam acts on multidrug-resistant *P. aeruginosa* strains that are
279 ESBL, AmpC and KPC positive, as this inhibitor removes the serine residue that is the
280 active portion of the enzyme, however, these antimicrobials do not act on metallo β -
281 lactamases positive strains [30], indicating the action of β -lactamases inhibitors in light
282 of the high positivity of the presence of genes encoding KPC in our study.

283 The susceptibility rates obtained in our study are in agreement with studies that
284 have reported good activity of ceftazidime associated with avibactam and ceftolozone
285 associated with tazobactam. López-Calleja and collaborators [31] carried out a study in
286 a university hospital located in Spain, in which they analyzed the susceptibility profile
287 of 12 MDR strains of *P. aeruginosa* and 117 XDR strains of *P. aeruginosa* against
288 ceftolozone associated with tazobactam, and detected a susceptibility rate of 92.2% in
289 these isolates. In the same context, research carried out by the Global Antimicrobial
290 Testing Leadership and Surveillance Program, collected 2.521 clinical isolates of *P.*
291 *aeruginosa* from 41 medical centers in 10 countries in Latin America, from 2017 to
292 2019, in which they found a rate of 86.9% of isolates susceptible to ceftazidime
293 associated with avibactam [32]. Therefore, these studies corroborate our results,
294 showing that third-generation cephalosporins in combination with β -lactamases
295 inhibitors are a good therapeutic option.

296 In order to identify the presence and prevalence of genes encoding β -lactamases
297 in the university hospital, we analyzed 14 genes, where the most prevalent gene was
298 *bla*_{KPC} with 81.49% positivity in the isolates. In a study carried out by Hu and
299 collaborators [33], researching strains of carbapenem-resistant *P. aeruginosa* isolated
300 from the intestine, from 2014 to 2019, the presence of the *bla*_{KPC-2} gene was identified in
301 21.1% of the isolates. Likewise, a prospective and observational cohort study, carried
302 out from 2018 to 2019, analyzed 972 patients admitted with confirmed infection by
303 carbapenem-resistant *P. aeruginosa* in 44 hospitals, distributed across three continents,
304 identifying the presence of the *bla*_{KPC-2} gene in 49% of isolates, demonstrating the
305 circulation of this gene that confers resistance to carbapenems in various parts of the
306 world [34]. Carbapenems have the widest spectrum of action for the treatment of
307 infections caused by multidrug-resistant bacteria, which is why the emergence and
308 spread of carbapenemases has become a major public health problem. Our study
309 detected a rate well above the studies cited, as we used a *bla*_{KPC} primer that detects 19
310 variants, expanding the detection of this β -lactamase, in contrast to just one variant that
311 the studies above investigated.

312 To understand the association of the β -lactam resistance phenotype with genes
313 related to β -lactamases, we correlated the phenotype and genotype and found a
314 statistical association between resistance to ceftazidime and cefepime with the presence
315 of the *bla*_{TEM} and *bla*_{OXA-23-like} genes. This can be explained by the fact that the *bla*_{TEM}
316 gene has several variants that are ESBLs, capable of hydrolyzing third and fourth
317 generation cephalosporins [35]. In this case, our study used primers that have the ability
318 to detect 167 variants of the *bla*_{TEM} gene, of which many of these variants are ESBLs.
319 Regarding the *bla*_{OXA-23-like} gene, which encodes an enzyme capable of hydrolyzing all
320 cephalosporins and carbapenems [36,37], was the first class D carbapenemase to be
321 discovered in a strain of *Acinetobacter baumannii*, in 1985, coincidentally the same
322 year that imipenem was approved for clinical use [38]. Genes belonging to the *bla*_{OXA-}
323 _{23-like} group can be transmitted by plasmids between species, in which studies have
324 detected the role of plasmids and transposons in the dissemination of the *bla*_{OXA-23} gene,
325 which has been found in *Acinetobacter* spp., *P. aeruginosa*, as well as species belonging
326 to the *Enterobacteriaceae* [36,39,40,41].

327 The presence of the *bla*_{TEM} gene was also associated with resistance to
328 carbapenems, imipenem and meropenem; there is no previous information in the
329 literature that corroborates this result in *P. aeruginosa*. However, a study carried out by

330 Han and colleagues [42], analyzing strains of *A. baumannii* resistant to carbapenems in
331 a university hospital in China, found an association between the presence of the *bla*_{TEM}
332 and *bla*_{OXA-23-like} genes with the carbapenem resistance phenotype. In research carried
333 out in an Iranian hospital, from 2015 to 2017, resistant strains of *P.aeruginosa* were
334 isolated from patients with nosocomial and non-nosocomial infections and the presence
335 of the *bla*_{OXA-23-like} gene was identified in 11.19% of the isolates [43], evidencing the
336 circulation of the OXA group gene in species other than *Acinetobacter*.

337 Finally, the presence of the *bla*_{OXA-51-like} gene was associated with resistance to
338 meropenem. *bla*_{OXA-51-like} encodes a carbapenemase belonging to Ambler class D, which
339 are enzymes intrinsic to *A. baumannii* and are found naturally in the chromosome of this
340 species [36], however, in 2009, Lee and colleagues reported the presence of the *bla*_{OXA-}
341 ₅₁ gene in a non-*Acinetobacter* species, in which they identified this gene with an
342 ISAbal insertion, which was plasmid-encoded and the surrounding sequences suggested
343 that its origin was from *A. baumannii*. In this study, the enzyme encoded by *bla*_{OXA-51}
344 had the capacity to increase the minimum inhibitory concentration (MIC) of meropenem
345 by up to 256 times, thus conferring resistance to it [44]. However, there is only one
346 study in the literature that reports the presence of the *bla*_{OXA-51} gene in *P. aeruginosa*
347 strains, which were isolated from outpatients in Maranhão, Brazil [45]. These studies
348 demonstrate the spread of the *bla*_{OXA-51} gene beyond strains of *A. baumannii*, where this
349 gene was considered a marker for these species.

350 Regarding the presence of Mex family efflux pumps in *P. aeruginosa* isolates,
351 our study showed a positivity of 96.3% for the gene that encodes the MexCD pump and
352 a positivity of 100% for the rest of the Mex pumps tested. There was no statistical
353 association of efflux pumps in relation to the resistance phenotype due to the high
354 positivity in the isolates, but studies have shown that efflux pumps in *P. aeruginosa* are
355 among one of the main resistance mechanisms that lead to the emergence of MDR
356 strains and XDR. This primary resistance mechanism is responsible for reducing the
357 intracellular concentration of the drug to a subinhibitory concentration at which other
358 resistance mechanisms for specific classes can evolve and be selected, increasing
359 antimicrobial resistance [46,47].

360 The present study had some limitations, such as: susceptible strains of *P.*
361 *aeruginosa* were not included in the study for a more detailed epidemiological analysis,
362 no research was carried out into the existence of clones of *P. aeruginosa* circulating in
363 the ICU, no sequencing was carried out positive controls for a more precise validation

364 of all variants that our method aims to detect and the isolates were not tested for all
365 antimicrobials in a homogeneous way due to clinical implications and procedures
366 adopted by the hospital analyzed in the study. However, our work innovated in the use
367 of primers that could detect a greater number of genes encoding β -lactamases, thus
368 expanding their diagnosis.

369 The *P. aeruginosa* strains isolated in this study showed a high rate of phenotypic
370 resistance to several antimicrobials, in which these strains have a repertoire of genes
371 encoding β -lactamases capable of inducing these phenotypic patterns of resistance to
372 antimicrobials commonly used for these infections, making treatment difficult or even
373 impossible for the patient.

374 **Author Contributions:**

375 Bibliographic review and data collection, Marília S. Maia, Lavouisier F.B. Nogueira,
376 Marco A.F Clementino and Aldo A.M. Lima; Methodology, Lavouisier F.B. Nogueira,
377 Marília S. Maia, Marco A.F Clementino, Alexandre Havt, Ila F.N. Lima, Jorge L.N.
378 Rodrigues, Luciana V. C. Fragoso and Aldo A. M. Lima; Bioinformatics, Lavouisier
379 F.B. Nogueira and Marco A.F Clementino; *In vitro* validation of primers and sample
380 testing, Marília S. Maia, Lavouisier F.B. Nogueira,; Data analysis, Jose Q.S. Filho;
381 Deiziane V.S. Costa, José K. Sousa, and Aldo A.M. Lima.

382 Written review and editing, Marília S. Maia, Lavouisier F.B. Nogueira, and Aldo A.M.
383 Lima; Supervision, Alexandre Havt and Aldo A.M. Lima; Project administration, Aldo
384 A.M. Lima; Resource acquisition, Aldo A.M. Lima.

385 **Funding:** This research was funded by CNPq (<http://www.cnpq.br>), grant numbers
386 402607/2018-0 and 408549/2022-0 and FUNCAP (<https://www.funcap.ce.gov.br/>),
387 grant number: OFÍCIO N° 102/2021 – DINOVA.

388 **Data Availability Statement:** The data and reports relating to this study will be
389 available via direct request via email to the corresponding author.

390 **Conflicts of Interest:** The authors declare that there are no financial or personal
391 conflicts of interest that may have influenced the work.

392 **References**

393 1. WHO. Media Center. WHO publishes list of bacteria for which new antibiotics are
394 urgently needed. World Health Organization: 27 Feb., 2017.


- 395 2. FLEECE, ME. et al. Molecular diagnosis of antimicrobial resistance in *Escherichia*
396 *coli*. **Expert Rev Mol Diagn**, v.18, n. 3, p.207-217, 2018.
- 397 3. AMARAL, MVF et al. Prevalência de microorganismos multirresistentes em um
398 hospital universitário - análise de uma série histórica. In: II Congresso Brasileiro de Medicina
399 Hospitalar - II CBMH. **Blucher Medical Proceedings**, v 1, n 5, p.70, 2014.
- 400 4. CARVALHO, MR. et al. Incidência de bactérias multirresistentes em uma unidade de
401 terapia intensiva. **Revista Interdisciplinar**, v.8, n.2, p. 75-85, 2015.
- 402 5. BOTELHO, J.; GROSSO, F.; PEIXE, L. Antibiotic resistance in *Pseudomonas*
403 *aeruginosa* – Mechanisms, epidemiology and evolution, **Drug Resistance Updates**, v. 44,
404 p.26–47, 2019.
- 405 6. JURADO-MARTÍN, I.; SAINZ-MEJÍAS, M.; MCCLEAN, S. *Pseudomonas*
406 *aeruginosa*: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. **Int. J.**
407 **Mol. Sci.** v.22, p.3128, 2021.
- 408 7. EUROPEAN CENTER FOR DISEASE PREVENTION AND CONTROL (ECDC),
409 Surveillance of antimicrobial resistance in Europe, Annual report of the European Antimicrobial
410 Resistance Surveillance Network (EARS-Net), 2016.
- 411 8. CAI, Y. et al. Prevalence of Healthcare- Associated Infections and Antimicrobial Use
412 Among Adult Inpatients in Singapore Acute-Care Hospitals: Results From the First National
413 Point Prevalence Survey. **Clin Infect Dis**. v.64, n. 2, p.S61–S67, 2017.
- 414 9. ROSSI, E. et al. *Pseudomonas aeruginosa* adaptation and evolution in patients with
415 cystic fibrosis. **Nat. Rev. Microbiol.** v.19, p.331–342, 2021.
- 416 10. ESCANDÓN-VARGAS K. et al. The epidemiology of carbapenemases in Latin
417 America and the Caribbean. **Expert Rev Anti Infect Ther**. 2017 Mar;15(3):277–297.
- 418 11. TENOVER, FC.; NICOLAU, DP.; Gill, CM. Carbapenemase-producing *Pseudomonas*
419 *aeruginosa* -an emerging challenge. **Emerg Microbes Infect.** v.11, n.1, p.811-814, 2022.
- 420 12. WALTERS MS. et al. Carbapenem- resistant *Pseudomonas aeruginosa* at US Emerging
421 infections program sites, 2015. **Emerging Infect Dis**. 2019 Jul;25(7):1281–1288.
- 422 13. LI, XZ.; PLÉSIAT, P.; NIKAIDO, H. The challenge of efflux-mediated antibiotic
423 resistance in Gram-negative bacteria. **Clin Microbiol Rev**. v. 28, n. 2, p.337-418, 2015.
- 424 14. LV, L. et al. Emergence of a Plasmid-Encoded Resistance-Nodulation-Division Efflux
425 Pump Conferring Resistance to Multiple Drugs, Including Tigecycline, in *Klebsiella*
426 *pneumoniae*. **mBio**, v.11, p.e02930-19, 2020.
- 427 15. NI, R. et al. The role of RND-type efflux pumps in multidrug-resistant mutants of
428 *Klebsiella pneumoniae*. **Nature**, v. 10, p.10876, 2020.
- 429 16. CLSI, Clinical and Laboratory Standards Institute, M100, 30th ed., January, 2020.
- 430 17. BrCAST, Brazilian Committee on Antimicrobial Susceptibility Testing, March, 2020.
- 431 18. BrCAST, Brazilian Committee on Antimicrobial Susceptibility Testing, May, 2021.

- 432 19. NOGUEIRA et al. Molecular insights of β -lactams resistance in *Klebsiella pneumoniae*
433 isolates with focus on multidrug resistance and virulence from colonization samples. **medRxiv**,
434 2023.
- 435 20. URZEDO, JE. et al. High mortality by nosocomial infections caused by carbapenem-
436 resistant *P. aeruginosa* in a referral hospital in Brazil: facing the perfect storm. **J Med**
437 **Microbiol.** v.69, n.12, p.1388-1397, 2020.
- 438 21. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA (ANVISA). REDE
439 NACIONAL DE MONITORAMENTO DA RESISTÊNCIA MICROBIANA EM SERVIÇOS
440 DE SAÚDE Boletim Segurança do Paciente e Qualidade em Serviços de Saúde nº 28 -
441 Avaliação Nacional dos indicadores de IRAS e RM, Brasília: ANVISA, 2021.
- 442 22. SADER HS, et al. Antimicrobial susceptibility of Gram-negative bacteria from
443 intensive care unit and non-intensive care unit patients from United States hospitals (2018-
444 2020). **Diagn Microbiol Infect Dis.** v.102, n. 1, p.115557, 2022.
- 445 23. DUNPHY LJ et al. Multidimensional Clinical Surveillance of *Pseudomonas aeruginosa*
446 Reveals Complex Relationships between Isolate Source, Morphology, and Antimicrobial
447 Resistance. **mSphere.** v. 6, n. 4, p. e0039321, 2021.
- 448 24. NUNES, L.H.D.S. et al., *Pseudomonas aeruginosa* in tracheal aspirate: Colonization,
449 infection, and recurrence. **Clin Respir J.** v.17, n.5, p.439-446, 2023.
- 450 25. BABICH, T. et al., Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single
451 Definitive Therapy for *Pseudomonas aeruginosa* Bloodstream Infection: A Multisite
452 Retrospective Study. **Clin Infect Dis.**, v.70, n.11, p.2270-2280, 2020.
- 453 26. FREIFELD, A.G. et al. Clinical practice guideline for the use of antimicrobial agents in
454 neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.
455 **Clin Infect Dis**, v.52, p.e56–e93, 2011.
- 456 27. SANTOS IC, Epidemiology and antibiotic resistance trends in clinical isolates of
457 *Pseudomonas aeruginosa* from Rio de Janeiro - Brazil: Importance of mutational mechanisms
458 over the years (1995-2015). **Infect Genet Evol.** v. 73, p. 411-415, 2019.
- 459 28. HAIDAR, G. et al. Ceftolozanetazobactam for the treatment of multidrug-resistant
460 *Pseudomonas aeruginosa* infections: clinical effectiveness and evolution of resistance. **Clin**
461 **Infect Dis.** v. 65, p. 110–120, 2017.
- 462 29. MUNITA, JM. Et al. Multicenter evaluation of ceftolozane/tazobactam for serious
463 infections caused by carbapenem-resistant *Pseudomonas aeruginosa*. **Clin Infect Dis.** v. 65, p.
464 158–161, 2017.
- 465 30. DRAWZ, SM.; PAPP-WALLACE, KM.; BONOMO, RA. New β -lactamase inhibitors:
466 a therapeutic renaissance in an MDR world. **Antimicrob Agents Chemother.** v. 58, p.1835–
467 1846, 2014.


- 468 31. LÓPEZ-CALLEJA, AI. et al., Antimicrobial activity of ceftolozane-tazobactam against
469 multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* clinical isolates
470 from a Spanish hospital. **Rev Esp Quimioter.** v.32, n.1, p.68-72, 2019.
- 471 32. KARLOWSKY, JA. et al. In vitro activity of ceftazidime-avibactam against
472 Enterobacterales and *Pseudomonas aeruginosa* isolates collected in Latin America as part of the
473 ATLAS global surveillance program, 2017-2019. **Braz J Infect Dis.** v.25, n.6, p.101647, 2021.
- 474 33. HU, Y. et al. Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal
475 Carbapenem-Resistant *Pseudomonas aeruginosa*. **Microbiol Spectr.** v.9, n.3, p.e0134421,
476 2021.
- 477 34. REYES, J. et al., Antibacterial Resistance Leadership Group and Multi-Drug Resistant
478 Organism Network Investigators. Global epidemiology and clinical outcomes of carbapenem-
479 resistant *Pseudomonas aeruginosa* and associated carbapenemases (POP): a prospective cohort
480 study. **Lancet Microbe.** v.4, n.3, p.e159-e170, 2023.
- 481 35. CASTANHEIRA, M.; SIMNER, P.; BRADFORD, P. Extended-spectrum b-lactamases:
482 an update on their characteristics, epidemiology and detection. **JAC Antimicrob Resist**, v. 16,
483 n. 3, p.1-21, 2021.
- 484 36. EVANS, BA.; AMYES, SG. OXA β -lactamases. **Clin Microbiol Rev.** v.27, n.2, p.241-
485 63, 2014.
- 486 37. KAITANY, KC. et al. Structures of the class D carbapenemases OXA-23 and OXA-146:
487 mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins and
488 aztreonam. **Antimicrob. Agents Chemother.** v.57, p.4848–4855, 2013.
- 489 38. LYON, J.A. Imipenem/cilastatin: the first carbapenem antibiotic. **Drug Intell. Clin.**
490 **Pharm.** v. 19, p.895– 899, 1985.
- 491 39. DIAS, V.C. et al. Epidemiological characteristics and antimicrobial susceptibility
492 among carbapenem-resistant non-fermenting bacteria in Brazil. **J Infect Dev Ctries.** v.10, n.6,
493 p.544-53, 2016.
- 494 40. LIU, LL. et al. Dissemination of blaOXA-23 in *Acinetobacter* spp. in China: main roles
495 of conjugative plasmid pAZJ221 and transposon Tn2009. **Antimicrob Agents Chemother.** v.
496 59, n.4, p.1998-2005, 2015.
- 497 41. ZONG, G. et al. The carbapenem resistance gene bla_{OXA-23} is disseminated by a
498 conjugative plasmid containing the novel transposon Tn6681 in *Acinetobacter johnsonii* M19.
499 **Antimicrob Resist Infect Control.** v. 9, n.1, p.182, 2020.
- 500 42. HAN, L et al. blaOXA-23-like and blaTEM rather than blaOXA-51-like contributed to a
501 high level of carbapenem resistance in *Acinetobacter baumannii* strains from a teaching hospital
502 in Xi'an, China. **Medicine (Baltimore)**,v. 96, n. 48, p.e8965, 2017.
- 503 43. ROUHI, S.; RAMAZANZADEH, R. Prevalence of bla_{Oxacillinase-23} and bla_{Oxacillinase-24/40}-
504 type Carbapenemases in *Pseudomonas aeruginosa* Species Isolated From Patients With

- 505 Nosocomial and Non-nosocomial Infections in the West of Iran. **Iran J Pathol.** v. 13, n. 3,
506 p.348-356, 2018.
- 507 44. LEE, YT. et al. First identification of bla_{OXA-51}-like in non-baumannii *Acinetobacter*
508 spp. **J Chemother.** v.21, n.5, p.514-20, 2009.
- 509 45. NITZ, F. et al. Molecular Detection of Drug-Resistance Genes of bla_{OXA-23}-bla_{OXA-51} and
510 *mcr-1* in Clinical Isolates of *Pseudomonas aeruginosa*. **Microorganisms.** v. 9, n.4, p. 786,
511 2021.
- 512 46. LORUSSO, AB. et al. Role of Efflux Pumps on Antimicrobial Resistance in
513 *Pseudomonas aeruginosa*. **Int J Mol Sci.** v.23, n.24, p.15779, 2022.
- 514 47. OLIVEIRA, W.K. et al. Resistome Analysis of Bloodstream Infection Bacterial
515 Genomes Reveals a Specific Set of Proteins Involved in Antibiotic Resistance and Drug Efflux.
516 **NAR Genom. Bioinforma.** v.2, p. lqaa055, 2020.

(B)




(A)




(A)

Genes encoding extended-spectrum β -lactamases
Ambler Class A



(B)

**Genes encoding carbapenemases
Ambler classes A and B**



(C)

**Genes encoding Ambler group D
carbapenemases**

